Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDOVA maintenance study of TEDOPI with or without Keytruda versus best supportive care in platinum-sensitive recurrent ovarian cancer
2024-516096-32-00Phase 2Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer comparing TEDOPI, TEDOPI + Keytruda and Best supportive care (3 arms). Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
Tedopipembrolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2024-516096-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516096-32-00.